Spanish consensus on premature menopause

Maturitas

Volumn 80, Issue 2, 2015, Pages 220-225

  Mendoza, Nicolás ^a   Juliá, MaDolores ^b   Galliano, Daniela ^c   Coronado, Pluvio ^d   Díaz, Begoña ^e   Fontes, Juan ^f   Gallo, José Luis ^f   García, Ana ^g   Guinot, Misericordia ^h   Munnamy, Merixtell ⁱ   Roca, Beatriz ^j   Sosak, Manuel ^k   Tomásj, Jordi ^j   Llaneza, Plácido ^l   Sánchez Borregom, Rafael ^m  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO VALENCIANO DE INFERTILIDAD   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ Sant Feliu de Llobregat   (Spain)

^j HOSPITAL MÚTUA DE TERRASSA   (Spain)

^k Hospital Universitario Materno Infantil de Canarias   (Spain)

^l UNIVERSITY OF OVIEDO   (Spain)

^m Clínica Diatros of Barcelona   (Spain)

more..

Author keywords

Fertility preservationFertility treatments; Hormonal therapy; Osteoporosis; Premature menopause; Primary ovarian insufficiency

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLOMIFENE CITRATE; CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; FERTILITY PROMOTING AGENT; GONADORELIN AGONIST; PRASTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; CONTRACEPTION; DISEASE ASSOCIATION; DRUG CHOICE; EARLY MENOPAUSE; ESTROGEN DEFICIENCY; FEMALE; FEMALE FERTILITY; FERTILITY PRESERVATION; FOLLOW UP; HORMONAL THERAPY; HUMAN; INFERTILITY THERAPY; MEDICAL EXPERT; MEDICAL SOCIETY; OVARY FUNCTION; PERSONAL EXPERIENCE; PREMATURE OVARIAN FAILURE; SPAIN; ADULT; COMPLICATION; CONSENSUS; EMBRYO DISPOSITION; ESTROGEN THERAPY; FERTILITY; INFERTILITY, FEMALE; OOCYTE; OOCYTE DONATION; OVARY FOLLICLE; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES;

ADULT; CONSENSUS; EMBRYO DISPOSITION; ESTROGEN REPLACEMENT THERAPY; FEMALE; FERTILITY; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; MENOPAUSE, PREMATURE; OOCYTE DONATION; OOCYTES; OVARIAN FOLLICLE; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; SOCIETIES, MEDICAL; SPAIN;

EID: 84922673956     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.11.007     Document Type: Article

References (44)

1. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet2010;376: 911-21.
2. Gold EB, Crawford SL, Avis NE, et al. Factors related to age at natural menopause: Longitudinal analyses from SWAN. Am J Epidemiol 2013;178: 70-83.
3. Progetto Menopausa Italia Study Group. Premature ovarian failure: Frequencyand risk factors among women attending a network of menopause clinics inItaly. BJOG 2003;110: 59-63.
4. Shah D, Nagarajan N. Premature menopause - meeting the needs. Post ReprodHealth 2014;20: 62-8.
5. Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI. Race/ethnicdisparities in reproductive age: An examination of ovarian reserve estimatesacross four race/ethnic groups of healthy, regularly cycling women. Fertil Steril2014;101: 199-207.
6. Freour T, Masson D, Mirallie S, et al. Active smoking compromises IVF outcomeand affects ovarian reserve. Reprod Biomed Online 2008;16: 96-102.
7. Eskenazi B, Warner M, Marks AR, et al. Serum dioxin concentrations and age atmenopause. Environ Health Perspect 2005;113: 858-62.
8. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin2012;62: 10-29.
9. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the humanoocyte. Hum Reprod 2003;18: 117-21.
10. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemother-apeutic agents damage the ovary. Hum Reprod Update 2012;18: 525-35.
11. Bines J, Oleske D, Cobleigh M. Ovarian function in premenopausal womentreated with adjuvant chemotherapy for breast cancer. J Clin Oncol1996;14: 1718-29.
12. Wallace WHB, Anderson RA, Irvine DS. Fertility preservation for youngpatients with cancer: Who is at risk and what can be offered. Lancet Oncol2005;6: 209-18.
13. van der Stege JG, Groen H, van Zaderlhoff SJ, et al. Decreased androgen con-centrations and diminished general and sexual wellbeing in women withpremature ovarian failure. Menopause 2008;15: 23-31.
14. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Prematuremenopause or early menopause: Long-term health consequences. Maturitas2010;65: 161-6.
15. Rocca WA, Grossardt BR, Miller VM, et al. Premature menopause or earlymenopause and risk of ischemic stroke. Menopause 2012;19: 272-7.
16. Rocca WA, Shuster LT, Grossard BR, et al. Long-term effects of bilateraloophorectomy on brain aging: Unanswered questions from de Mayo ClinicCohort Study of Oophorectomy and Aging. Womens Health (Lond Engl)2009;5: 39-48.
17. Ferrarini E, Russo L, Fruzzetti F, et al. Clinical characteristics and geneticanalysis in women with premature ovarian insufficiency. Maturitas 2013;74: 61-7.
18. Ramezani Tehrani F, Dólleman M, van Disseldorp J, et al. Predicting menopausalage with anti-Müllerian hormone: A cross-validation study of two existingmodels. Climacteric 2014;10: 1-8.
19. Mintziori G, Lambrinoudaki I, Ceausu I, et al. EMAS position statement: Fertilitypreservation. Maturitas 2014;77: 85-9.
20. Cobo A, Diaz C. Clinical application of oocyte vitrification: A system-atic review and meta-analysis of randomized controlled trials. Fertil Steril2011;96: 277-85.
21. Rodriguez-Wallberg KA, Oktay K. Options on fertility preservation in femalecancer patients. Cancer Treat Rev 2012;38: 354-61.
22. Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVFtreatment. Hum Reprod 2011;26: 2593-7.
23. Martin JR, Kodaman P, Oktay K, et al. Ovarian cryopreservation with transpo-sition of a contralateral ovary: A combined approach for fertility preservationin women receiving pelvic radiation. Fertil Steril 2007;189: E5-7.
24. Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Orthotopic andheterotopic ovarian tissue transplantation. Hum Reprod Update 2009;6: 649-65.
25. Clowse M, Behera M, Anders C, et al. Ovarian preservation by GnRH ago-nists during chemotherapy: A meta-analysis. J Womens Health 2009;18: 311-9.
26. Pruthi S, Gostout BS, Lindor NM. Identification and management of women withBRCA mutations or hereditary predisposition for breast and ovarian cancer.Mayo Clin Proc 2010;85: 1111-20.
27. Ben-Nagi J, Panay N. Premature ovarian insufficiency: How to improve repro-ductive outcome. Climacteric 2013;17: 242-6.
28. Tartagni M, Cicinelli E, De Pergola G, De Salvia M, Lavopa C, Loverro G. Effectsof pretreatment with estrogens on ovarian stimulation with gonadotropins inwomen with premature ovarian failure: A randomized, placebo controlled trial.Fertil Steril 2007;87: 858-61.
29. Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turnersyndrome: A guideline of the Turner Syndrome Study Group. J Clin EndocrinolMetab 2007;92: 10-25.
30. Yeung TW, Li RH, Lee VC, Ho PC, Ng EH. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks onovarian response markers in women with primary ovarian insufficiency. J ClinEndocrinol Metab 2013;98: 380-8.
31. Tilly JL, Sinclair DA. Germline energetics, aging, and female infertility. CellMetab 2013;17(June (6)): 838-50.
32. Hagman A, Källén K, Bryman I, Landin-Wilhelmsen K, Barrenäs ML, Wen-nerholm UB. Morbidity and mortality after childbirth in women with Turnerkaryotype. Hum Reprod 2013;28: 1961-73.
33. de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women withpremature ovarian failure. Menopause 2011;18: 262-6.
34. de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statementon menopausal hormone therapy. Maturitas 2013;74: 391-2
35. Mendoza N, Suárez AM, Álamo F, Bartual E, Vergara F, Herruzo A. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17ß-estradiol forhormonal replacement therapy in women with surgical menopause. Maturitas2000;37(1): 37-43.
36. van der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: Increasedfracture risk at older age. Osteoporos Int 2003;14: 525-30.
37. Sanchez Borrego R, Mendoza N, Beltran E, et al. Position of the SpanishMenopause Society regarding the management of menopausal symptoms inbreast cancer patients. Maturitas 2013;75: 294-300.
38. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators inprevention of breast cancer: An updated meta-analysis of individual participantdata. Lancet 2013;381: 1827-34.
39. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen recep-tor modulator raloxifene on coronary outcomes in the Raloxifene Use for TheHeart trial: Results of subgroup analyses by age and other factors. Circulation2009;119: 922-30.
40. Mendoza N, Sánchez-Borrego R, Villero J, et al. Up-date of the consensus state-ment of the Spanish Menopause Society on postmenopausal osteoporosis.Maturitas 2013;76: 99-107.
41. Mendoza N, Sanchez-Borrego R, Cancelo MJ, et al. Position of the SpanishMenopause Society regarding the management of perimenopause. Maturitas2013;74: 283-90.
42. Lete I, Bermejo R, Parrilla JJ, et al. Use of contraceptive methods and risk ofunwanted pregnancy in Spanish women aged 40-50 years: Results of a surveyconducted in Spain. Eur J Contracept Reprod Health Care 2007;12: 46-50.
43. Bleil ME, Bromberger JT, Latham MD, et al. Disruptions in ovarian functionare related to depression and cardiometabolic risk during premenopause.Menopause 2013;20: 631-9.
44. James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management ofacute menorrhagia in women with and without underlying bleeding disorders: Consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol2011;158: 124-34.